Trial Outcomes & Findings for The Zeaxanthin and Visual Function Study (NCT NCT00564902)

NCT ID: NCT00564902

Last Updated: 2012-03-29

Results Overview

Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

60 participants

Primary outcome timeframe

4 months

Results posted on

2012-03-29

Participant Flow

Subjects were patients in the Ophthalmology/Optometry Clinic North Chicago DVA Medical Center (now the James A. Lovell Federal Health Center)with early and moderate AMD retinopathy up to, but not including,high risk NEI AREDS retinopathy.

No enrolled participant was excluded before assignment to groups. Patients were asked to continue with their normal diet and were asked not to take any dietary supplement containing lutein (or zeaxanthin) beyond the 250 ug (1/4mg) commonly found in pabulum Centrum® type vitamins.

Participant milestones

Participant milestones
Measure
Lutein
Lutein 9 mg per day
Lutein Zeaxanthin
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
3R 3'R Zeaxanthin 8 mg per day during 12 months
Overall Study
STARTED
10
25
25
Overall Study
4 Months
9
24
23
Overall Study
8 Months
9
22
21
Overall Study
12 Months
9
21
21
Overall Study
COMPLETED
9
21
21
Overall Study
NOT COMPLETED
1
4
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Lutein
Lutein 9 mg per day
Lutein Zeaxanthin
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
3R 3'R Zeaxanthin 8 mg per day during 12 months
Overall Study
Withdrawal by Subject
0
3
4
Overall Study
Death
1
1
0

Baseline Characteristics

The Zeaxanthin and Visual Function Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Lutein
n=10 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=25 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=25 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
Total
n=60 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Age, Categorical
Between 18 and 65 years
3 Participants
n=99 Participants
5 Participants
n=107 Participants
4 Participants
n=206 Participants
12 Participants
n=7 Participants
Age, Categorical
>=65 years
7 Participants
n=99 Participants
20 Participants
n=107 Participants
21 Participants
n=206 Participants
48 Participants
n=7 Participants
Age Continuous
73.9 years
STANDARD_DEVIATION 9 • n=99 Participants
75.8 years
STANDARD_DEVIATION 9 • n=107 Participants
74.4 years
STANDARD_DEVIATION 11 • n=206 Participants
74.9 years
STANDARD_DEVIATION 10 • n=7 Participants
Sex: Female, Male
Female
1 Participants
n=99 Participants
1 Participants
n=107 Participants
1 Participants
n=206 Participants
3 Participants
n=7 Participants
Sex: Female, Male
Male
9 Participants
n=99 Participants
24 Participants
n=107 Participants
24 Participants
n=206 Participants
57 Participants
n=7 Participants
Macular Pigment Optical Density
0.37 Density units of macular pigment
STANDARD_DEVIATION 0.05 • n=99 Participants
0.29 Density units of macular pigment
STANDARD_DEVIATION 0.06 • n=107 Participants
0.35 Density units of macular pigment
STANDARD_DEVIATION 0.04 • n=206 Participants
0.33 Density units of macular pigment
STANDARD_DEVIATION 0.05 • n=7 Participants
Early Treatment Diabetic Retinopathy Study distance visual acuity
93.3 units on a scale
STANDARD_DEVIATION 8 • n=99 Participants
86.8 units on a scale
STANDARD_DEVIATION 12 • n=107 Participants
88.3 units on a scale
STANDARD_DEVIATION 10 • n=206 Participants
88.7 units on a scale
STANDARD_DEVIATION 13 • n=7 Participants
Glare Recovery
52.9 Seconds
STANDARD_DEVIATION 16 • n=99 Participants
35.6 Seconds
STANDARD_DEVIATION 6 • n=107 Participants
26.7 Seconds
STANDARD_DEVIATION 5 • n=206 Participants
34.1 Seconds
STANDARD_DEVIATION 30 • n=7 Participants
Contrast Sensitivity Function Photopic Distance
212 units on a scale
STANDARD_DEVIATION 34 • n=99 Participants
204 units on a scale
STANDARD_DEVIATION 30 • n=107 Participants
201 units on a scale
STANDARD_DEVIATION 22 • n=206 Participants
204 units on a scale
STANDARD_DEVIATION 125 • n=7 Participants
Shape Discrimination
0.7 % modulation
STANDARD_DEVIATION 0.2 • n=99 Participants
0.7 % modulation
STANDARD_DEVIATION 0.1 • n=107 Participants
1 % modulation
STANDARD_DEVIATION 0.2 • n=206 Participants
0.8 % modulation
STANDARD_DEVIATION 0.8 • n=7 Participants
6.5 degrees Tritan threshold
4.9 (dB)
STANDARD_DEVIATION 4 • n=99 Participants
8.6 (dB)
STANDARD_DEVIATION 12 • n=107 Participants
6 (dB)
STANDARD_DEVIATION 9 • n=206 Participants
6.9 (dB)
STANDARD_DEVIATION 10 • n=7 Participants
100% Kinetic Field
5514 Units on a scale (0 to 6000)
STANDARD_DEVIATION 2074 • n=99 Participants
1717 Units on a scale (0 to 6000)
STANDARD_DEVIATION 765 • n=107 Participants
2649 Units on a scale (0 to 6000)
STANDARD_DEVIATION 750 • n=206 Participants
2738 Units on a scale (0 to 6000)
STANDARD_DEVIATION 4471 • n=7 Participants

PRIMARY outcome

Timeframe: 4 months

Population: All participants in all arms were tested

Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=24 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=23 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
Macular Pigment Optical Density
0.48 Density units of Macular Pigment (du)
Standard Error .05
0.38 Density units of Macular Pigment (du)
Standard Error .06
0.42 Density units of Macular Pigment (du)
Standard Error .04

PRIMARY outcome

Timeframe: 8 months

Population: All participants in all arms were tested

Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering LED's and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated. The method has good repeatability (r = 0.97) and the data are comparable with an objective optical method based on retinal reflectometry (r = 0.78).

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=22 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
Macular Pigment Optical Density
0.48 Density units of Macular Pigment (du)
Standard Error 0.05
0.44 Density units of Macular Pigment (du)
Standard Error 0.06
0.46 Density units of Macular Pigment (du)
Standard Error 0.04

PRIMARY outcome

Timeframe: 12 months

Population: All participants in all arms were tested

Replicate measures of foveal 1 degree estimated central MPOD were evaluated with the Quantify® MPS 9000 macular pigment screener, a modified heterochromic flicker photometer (HFP). It employs alternating blue and green flickering light emitting diodes and fixation on a 1 degree target, so that a representative measurement at 0.5 degree off center from the fovea is calculated.

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
Macular Pigment Optical Density
0.54 Density units of Macular Pigment (du)
Standard Error 0.05
0.52 Density units of Macular Pigment (du)
Standard Error 0.06
0.48 Density units of Macular Pigment (du)
Standard Error 0.04

SECONDARY outcome

Timeframe: 12 months

Population: Eyes of all participants still in the trial were measured

We determined the target deformation detection thresholds, or amplitude of the minimum detectable distortion of a 1 degree foveal circular target. The peak spatial frequency of RF (radial frequency) patterns was 5 cyc/deg; the radial modulation frequency was 8 cyc/360°; mean radii were 0.5°, 1°, 2.0°, or 2.5°; and stimulus contrast was 80%. The highest % modulation score possible is 0.13 while the easiest (lowest score) was 10% modulation.

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
SHAPE Discrimination
0.5 % modulation
Standard Deviation .24
0.6 % modulation
Standard Deviation 0.25
0.6 % modulation
Standard Deviation .46

SECONDARY outcome

Timeframe: 12 months

Population: Eyes of all patients still in the trial were measured

Black and 10% contrast near reading visual acuity was assessed with a Colenbrander Mixed Contrast Reading Card with LogMAR letters (#4031, Precision Vision, LaSalle, Illinois). We determined single letter acuity on an ordinal VAS (Visual Acuity Scale). The largest letters were 0.05 LogMAR with a VAS = 35 while the most difficult smallest letters were LogMar 1.25 or VAS 105. The test card was held at 40 cm with best monocular refraction, and both low and high contrast letter acuity were assessed.

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
Early Treatment Diabetic Retinopathy Study Distance Visual Acuity
98.9 units on a scale
Standard Error 5.7
92.8 units on a scale
Standard Error 5.9
96.8 units on a scale
Standard Error 8.35

SECONDARY outcome

Timeframe: 12 Months

Population: Eyes of all patients still in the trial were measured

Photostress glare recovery test involves exposing an individual eye to intense light, or retinal bleach, for a set duration of time and measuring the time taken for visual acuity to recover to a predetermined level. Glare photo-stress recovery (in seconds) following 30 seconds of continuous retinal bleach, was assessed using 2 line supra-threshold low contrast randomly presented Landolt Cs using the KOWA AS14B Night Vision Tester (KOWA Optimed, Tokyo, Japan).

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
Glare Recovery
25.2 Seconds
Standard Error 28.5
14.85 Seconds
Standard Error 22
16.65 Seconds
Standard Error 10.25

SECONDARY outcome

Timeframe: 12 Months

Population: Eyes of all patients still in the trial were measured

Distance photopic contrast sensitivity function (CSF) at 5 spatial frequencies (1.5, 3, 6, 12 \& 20 cc/deg) was determined with the Functional Vision Analyzer® (Stereo Optical Co, Inc, Chicago, IL). Contrast sensitivity readings are shown as a curve. Visual acuity is plotted along the horizontal axis and contrast sensitivity along the vertical axis. Among the normally sighted people, both visual acuity and contrast sensitivity have a wide range of variation.Low population CSF is 0-200 units; normal population CSF is 200-300 units and suprathreshold CSF is 300+ units.

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
Contrast Sensitivity Function Photopic Distance
310.5 units on a scale
Standard Error 33.8
247.1 units on a scale
Standard Error 35
254.7 units on a scale
Standard Error 35.2

SECONDARY outcome

Timeframe: 12 months

Population: Eyes of all patients still in the trial were measured

The ChromaTest© is a computerized psychophysical test of protan and tritan color thresholds against age-corrected data. The computer finds the endpoint of the test by a Modified Binary Search method; if response is correct, on the next presentation the color difference between letter and background is halved. If response is incorrect, the color -contrast is doubled. Incorrect responses prolong the test, but do not influence the final threshold. This method of determining thresholds leads to finite steps which reach a plateau at the color contrast sensitivity threshold.

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
6.5 Degrees Tritan Threshold
4.46 dB
Standard Error 1.08
8.37 dB
Standard Error 1.39
3.45 dB
Standard Error 1.09

SECONDARY outcome

Timeframe: 12 Months

Population: Eyes of all patients still in the trial were measured

Scotomas within the central 20 degree central macula visual field sensitivity was assessed at 5 contrast levels (20, 40, 60, 80, and full contrast). A yellow wavelength stimulus avoided confounding by the lens. Subjects outlined the boundaries of their scotoma(s) on an area-integrating and recording touch flat- screen RGB monitor displaying a central fixation point and movable horizontal/vertical raster lines. The computer calculated summed area of the scotoma(s) with arbitrary scaling from 6000 (dense scotoma) to 0 relative units (absence of scotoma).

Outcome measures

Outcome measures
Measure
Lutein
n=9 Participants
Lutein 9 mg per day
Lutein Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
Zeaxanthin
n=21 Participants
3R 3'R Zeaxanthin 8 mg per day during 12 months
100% Kinetic Field
2704 Units on a scale (0 to 6000)
Standard Error 1745
2207 Units on a scale (0 to 6000)
Standard Error 210
1129 Units on a scale (0 to 6000)
Standard Error 650

Adverse Events

Lutein

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Lutein Zeaxanthin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Zeaxanthin

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Stuart P. Richer

James A. Lovell Federal Health Care Center

Phone: 224-610-5440

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place